Liquidia (NASDAQ:LQDA) Stock Price Down 4.3%

Liquidia Co. (NASDAQ:LQDA) shares traded down 4.3% on Thursday . The stock traded as low as $9.72 and last traded at $9.72. 710,279 shares were traded during mid-day trading, a decline of 29% from the average session volume of 1,001,245 shares. The stock had previously closed at $10.16.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LQDA. HC Wainwright decreased their price objective on Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price objective on shares of Liquidia in a research note on Monday, August 19th. Bank of America decreased their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. BTIG Research dropped their price target on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, August 19th. Finally, Oppenheimer began coverage on shares of Liquidia in a report on Tuesday, June 25th. They issued a “market perform” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.14.

Liquidia Trading Down 4.2 %

The stock has a market capitalization of $742.74 million, a PE ratio of -6.53 and a beta of 0.22. The business’s 50-day moving average is $11.09 and its two-hundred day moving average is $12.75.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. On average, analysts predict that Liquidia Co. will post -1.71 EPS for the current year.

Insider Activity

In other news, Director Caligan Partners Lp acquired 150,000 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was bought at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the transaction, the director now directly owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Liquidia news, Director Caligan Partners Lp bought 150,000 shares of Liquidia stock in a transaction dated Friday, August 30th. The stock was bought at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the purchase, the director now owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Roger Jeffs sold 8,053 shares of Liquidia stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total transaction of $100,904.09. Following the completion of the sale, the chief executive officer now owns 818,932 shares of the company’s stock, valued at approximately $10,261,217.96. The disclosure for this sale can be found here. Insiders have sold 21,422 shares of company stock worth $256,998 over the last 90 days. Company insiders own 31.60% of the company’s stock.

Institutional Trading of Liquidia

Institutional investors have recently added to or reduced their stakes in the business. Patient Square Capital LP bought a new stake in shares of Liquidia during the 1st quarter valued at about $105,942,000. Farallon Capital Management LLC bought a new position in Liquidia during the 1st quarter worth $30,311,000. Vestal Point Capital LP acquired a new stake in Liquidia in the fourth quarter worth $12,331,000. Kynam Capital Management LP lifted its stake in Liquidia by 34.9% in the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock valued at $32,461,000 after buying an additional 698,324 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Liquidia by 119.4% during the first quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after acquiring an additional 125,315 shares during the period. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).